This trial was registered at www.clinicaltrials.gov as #NCT02447666.doi:10.1182/bloodadvances.2020004144Charlotte M.NiemeyerDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Freiburg, Germany.Christian.Flotho...
BACKGROUND:In the AZA-001 trial, azacitidine (75 mg/m2/d subcutaneously for Days 1-7 of every 28-day cycle) demonstrated improved survival compared with co... LR Silverman,P Fenaux,GJ Mufti,... - 《Cancer》 被引量: 451发表: 2011年 Phase 2 study of the lenalidomide and azacitidine co...
Context:In the QUAZAR AML-001 trial, Oral-AZA significantly prolonged OS vs placebo (median 24.7 vs 14.8 months; P<0.001) in patients with AML in remission after IC and ineligible for transplant. At the primary data cutoff (July 2019) Kaplan-Meier (KM) OS curves for Oral-AZA and placebo...
About 33% of patients (pts) in AZA-AML-001 had AML with morphologic dysplastic changes (AML-MDC).Aim: Determine effects of AZA vs CCR on OS, response, and safety in the subset of pts with AML-MDC in the AZA-AML-001 trial; and further analyze OS in AML-MDC pts who had been ...